- Title: Subtitle
- P-263: Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
- Creators
- Philippe MoreauSaad UsmaniNiels W.C.J. van de DonkAlfred GarfallMichel DelforgeAlbert OriolAjay NookaLaura RosiñolNizar BahlisPaula Rodríguez-OteroThomas MartinJoris DielsSuzy Van SandenLixia PeiEric AmmannRachel KobosAlexander MarshallMary SlavcevJennifer SmitAnil LondheAmrita Krishnan
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S181-S182
- DOI
- 10.1016/S2152-2650(22)00593-6
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Language
- English
- Date published
- 08/2022
- Academic Unit
- Epidemiology
- Record Identifier
- 9984364361202771
Abstract
P-263: Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S181-S182
08/2022
DOI: 10.1016/S2152-2650(22)00593-6
Details
Metrics
18 Record Views